Privately held biotechnology company developing psilocybin-based treatments for mental-health conditions in patients with life-altering diseases. It holds an exclusive worldwide license from NYU Langone Health for psilocybin intellectual property and licensed Filament Health's botanical psilocybin candidate PEX010. Its lead candidate RSTP1000, an oral psilocybin, received FDA 'Safe to Proceed' clearance for a Phase 2b trial in demoralization syndrome in cancer patients.